Disitamab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade

Introduction

Disitamab Biosimilar, also known as Anti-ERBB2, EGFR2, CD340 mAb, is a monoclonal antibody that has been developed as a biosimilar to the widely used anti- cancer drug, Trastuzumab. This biosimilar has shown promising results in pre-clinical and clinical studies, and is being considered as a potential therapeutic option for various types of cancers.

Structure of Disitamab Biosimilar

Disitamab Biosimilar is a recombinant, humanized monoclonal antibody that specifically targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2), also known as ERBB2 or EGFR2. It is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two identical antigen-binding fragments (Fab) and one constant fragment (Fc). The Fab region is responsible for binding to the HER2 receptor, while the Fc region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Disitamab Biosimilar Disitamab Biosimilar exerts its anti-

cancer activity primarily by binding to the HER2 receptor, which is overexpressed in many types of cancer cells. This binding inhibits the activation of HER2 signaling pathways, which are known to promote cell growth, survival, and proliferation. By blocking these pathways, Disitamab Biosimilar can induce cell cycle arrest, inhibit tumor growth, and promote cell death in HER2-positive cancer cells. Additionally, the Fc region of the antibody can also activate the immune system to attack and destroy cancer cells through ADCC and CDC mechanisms.

Application of Disitamab Biosimilar

Disitamab Biosimilar has shown promising results in pre-clinical and clinical studies for the treatment of various types of cancers, including breast, gastric, and lung cancers. Its primary indication is for the treatment of HER2-positive breast cancer, either as a first-line therapy or in combination with other anti- cancer drugs. In addition, Disitamab Biosimilar has also shown potential as a therapeutic option for HER2-positive gastric cancer, with promising results in both pre-clinical and clinical studies. Furthermore, ongoing clinical trials are evaluating the efficacy of Disitamab Biosimilar in other types of cancers, such as lung and ovarian cancer.

Advantages of Disitamab Biosimilar

As a biosimilar to Trastuzumab, Disitamab Biosimilar offers several advantages over the originator drug. Firstly, it has a similar structure and mechanism of action, making it highly comparable to Trastuzumab in terms of efficacy and safety. Additionally, Disitamab Biosimilar is produced using recombinant DNA technology, which allows for a more consistent and cost-effective production process. This could potentially lead to a lower cost of treatment for patients. Furthermore, as a biosimilar, Disitamab Biosimilar has undergone extensive comparability studies to demonstrate its similarity to Trastuzumab, ensuring its quality and efficacy.

Conclusion

Disitamab Biosimilar, a monoclonal antibody targeting HER2, has shown promising results as a biosimilar to Trastuzumab in the treatment of various types of cancers. Its similar structure and mechanism of action, along with its potential cost-effectiveness, make it a promising therapeutic option for HER2-positive cancers. Ongoing clinical trials will provide further insights into the efficacy and safety of this biosimilar, potentially expanding its application to other types of cancers.